Sun Pharma Makes a Bold Move: Acquires Checkpoint Therapeutics for $355 Million

Sun Pharmaceutical Industries is taking over Checkpoint Therapeutics, a Nasdaq-listed oncology and immunotherapy company, for as much as $355 million. The transaction involves UNLOXCYT, an FDA-approved therapy for advanced skin cancer, that will add to Sun Pharma's onco-derm therapy portfolio. Shareholders will be paid $4.10 per share, with possible additional consideration if cosibelimab receives approval in Europe. The transaction is anticipated to close in Q2 2025, pending regulatory approvals.

 

Source: Sun Pharma, NSE, BSE, Reuters